Top

Cancer Cell International

Published in:

Open Access 01-12-2020 | Primary research

Identification of metabolism-associated genes and construction of a prognostic signature in bladder cancer

Authors: Chengquan Shen, Jing Liu, Liping Wang, Zhijuan Liang, Haitao Niu, Yonghua Wang

Published in: Cancer Cell International | Issue 1/2020

Abstract

Background

Bladder cancer (BC) is a commonly diagnosed malignant tumor in the urinary system, with a high morbidity and a high recurrence rate. Current studies indicated that metabolism-associated genes (MAGs) having critical roles in the etiology of BC. The present study aims to identify differentially expressed MAGs and construct a MAGs based prognostic risk signature for BC by using The Cancer Genome Atlas (TCGA) database and proteomics data.

Methods

RNA-sequence data from the TCGA database and proteomics data from our BC samples were used to identify differentially expressed MAGs and construct a MAGs based prognostic signature in BC. Subsequently, survival analysis and nomogram were used to evaluate the prognostic and predictive value of the MAGs based signature in BC. RNA isolation and reverse transcription‑quantitative PCR (RT-qPCR) were further performed to investigate the expression levels of MAGs in BC cells and explore the relationship between MAGs and M2 tumor associated macrophages (TAMs) secreted transforming growth factor-β1 (TGF-β1) in BC cells.

Results

A total of 23 differentially expressed MAGs were identified and five MAGs were finally used to construct a MAGs based signature. Survival analysis revealed that the MAGs based signature was closely correlated with the survival outcomes of patients with BC. A nomogram with the MAGs based signature risk score and clinical features was also constructed to facilitate the individualized prediction of BC patients. RT-qPCR showed that five MAGs were significantly differentially expressed and the expression levels of three MAGs were positively correlated with M2 TAMs secreted TGF-β1 in T24 cells.

Conclusions

Our study identified novel prognostic MAGs and constructed a MAGs based signature, which can be used as an independent factor in evaluating the prognosis of patients with BC. Furthermore, M2 TAMs may promote the expression of MAGs via the TGF-β1 signaling pathway in the microenvironment of BC. Further clinical trials and experimental explorations are needed to validate our observations in BC.

Available only for authorised users

Antoni S, Ferlay J, Soerjomataram I, et al. Eur Urol. 2017;71(1):96–108. https://doi.org/10.1016/j.eururo.2016.06.010.CrossRefPubMed

Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.CrossRefPubMed

Montironi R, Cheng L, Scarpelli M, Lopez-Beltran A. Pathology and genetics: tumours of the urinary system and male genital system: clinical implications of the 4th Edition of the WHO classification and beyond. Eur Urol. 2016;70(1):120–3. https://doi.org/10.1016/j.eururo.2016.03.011.CrossRefPubMed

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

Locasale JW, Cantley LC, Vander Heiden MG. Cancer’s insatiable appetite. Nat Biotechnol. 2009;27(10):916–7. https://doi.org/10.1038/nbt1009-916.CrossRefPubMedPubMedCentral

Röhrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16(11):732–49. https://doi.org/10.1038/nrc.2016.89.CrossRefPubMed

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33. https://doi.org/10.1126/science.1160809.CrossRefPubMedPubMedCentral

Massari F, Ciccarese C, Santoni M, et al. Metabolic phenotype of bladder cancer. Cancer Treat Rev. 2016;45:46–57. https://doi.org/10.1016/j.ctrv.2016.03.005.CrossRefPubMed

Cheng S, Wang G, Wang Y, et al. Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer. Clin Sci (Lond). 2019;133(15):1745–58. https://doi.org/10.1042/CS20190587.CrossRefPubMed

10.

Zhou Q, Zhan H, Lin F, et al. LincRNA-p21 suppresses glutamine catabolism and bladder cancer cell growth through inhibiting glutaminase expression. Biosci Rep. 2019;39(4):BSR20182372. https://doi.org/10.1042/bsr20182372.CrossRefPubMedPubMedCentral

11.

Stachowiak M, Szymanski M, Ornoch A, et al. SWI/SNF chromatin remodeling complex and glucose metabolism are deregulated in advanced bladder cancer. IUBMB Life. 2020;72(6):1175–88. https://doi.org/10.1002/iub.2254.CrossRefPubMedPubMedCentral

12.

Li T, Jiang D, Wu K. p62 promotes bladder cancer cell growth by activating KEAP1/NRF2-dependent antioxidative response. Cancer Sci. 2020;111(4):1156–64. https://doi.org/10.1111/cas.14321.CrossRefPubMedPubMedCentral

13.

Vantaku V, Putluri V, Bader DA, et al. Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene. 2019. https://doi.org/10.1038/s41388-019-0902-7.CrossRefPubMedPubMedCentral

14.

Loras A, Trassierra M, Sanjuan-Herráez D, et al. Bladder cancer recurrence surveillance by urine metabolomics analysis. Sci Rep. 2018;8(1):9172. https://doi.org/10.1038/s41598-018-27538-3.CrossRefPubMedPubMedCentral

15.

Cheng Y, Yang X, Deng X, et al. Metabolomics in bladder cancer: a systematic review. Int J Clin Exp Med. 2015;8(7):11052–63.PubMedPubMedCentral

16.

Piyarathna DWB, Rajendiran TM, Putluri V, et al. Distinct lipidomic landscapes associated with clinical stages of urothelial cancer of the bladder. Eur Urol Focus. 2018;4(6):907–15. https://doi.org/10.1016/j.euf.2017.04.005.CrossRefPubMed

17.

Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–8. https://doi.org/10.1093/nar/gkw937.CrossRefPubMed

18.

Zhou Y, Jin Z, Wang C. Glycogen phosphorylase B promotes ovarian cancer progression via Wnt/β-catenin signaling and is regulated by miR-133a-3p. Biomed Pharmacother. 2019;120:109449. https://doi.org/10.1016/j.biopha.2019.109449.CrossRefPubMed

19.

Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2018;174(4):1033. https://doi.org/10.1016/j.cell.2018.07.036.CrossRefPubMed

20.

Shen C, Liu J, Wang J, et al. Development and validation of a prognostic immune-associated gene signature in clear cell renal cell carcinoma. Int Immunopharmacol. 2020;81:106274. https://doi.org/10.1016/j.intimp.2020.106274.CrossRefPubMed

21.

Chanput W, Mes JJ, Wichers HJ. THP-1 cell line: an in vitro cell model for immune modulation approach. Int Immunopharmacol. 2014;23(1):37–45. https://doi.org/10.1016/j.intimp.2014.08.002.CrossRefPubMed

22.

Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65. https://doi.org/10.1016/j.ccr.2014.01.009.CrossRefPubMedPubMedCentral

23.

Sjödahl G, Lauss M, Lövgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377–86. https://doi.org/10.1158/1078-0432.CCR-12-0077-T.CrossRefPubMed

24.

Choi W, Czerniak B, Ochoa A, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(7):400–10. https://doi.org/10.1038/nrurol.2014.129.CrossRefPubMed

25.

Conde VR, Oliveira PF, Nunes AR, et al. The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism. Exp Cell Res. 2015;335(1):91–8. https://doi.org/10.1016/j.yexcr.2015.04.007.CrossRefPubMed

26.

Wu X, Li X, Fu Q, et al. AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program. J Exp Med. 2017;214(4):1065–79. https://doi.org/10.1084/jem.20160903.CrossRefPubMedPubMedCentral

27.

Khayami R, Hashemi SR, Kerachian MA. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. J Cell Mol Med. 2020;24(16):8890–902. https://doi.org/10.1111/jcmm.15581.CrossRefPubMedCentralPubMed

28.

Gu S, Feng XH. TGF-β signaling in cancer. Acta Biochim Biophys Sin (Shanghai). 2018;50(10):941–9. https://doi.org/10.1093/abbs/gmy092.CrossRef

29.

Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506–20. https://doi.org/10.1038/nrc1926.CrossRefPubMed

30.

Dumont N, Arteaga CL. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell. 2003;3(6):531–6. https://doi.org/10.1016/s1535-6108(03)00135-1.CrossRefPubMed

31.

Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007;8(12):970–82. https://doi.org/10.1038/nrm2297.CrossRefPubMed

32.

Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19(23):2783–810. https://doi.org/10.1101/gad.1350705.CrossRefPubMed

33.

Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol. 2005;21:659–93. https://doi.org/10.1146/annurev.cellbio.21.022404.142018.CrossRefPubMed

34.

Mazza G, Telese A, Al-Akkad W, et al. Cirrhotic human liver extracellular matrix 3d scaffolds promote smad-dependent TGF-β1 epithelial mesenchymal transition. Cells. 2019;9(1):83. https://doi.org/10.3390/cells9010083.CrossRefPubMedCentral

35.

Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–72. https://doi.org/10.1038/cr.2009.5.CrossRefPubMed

36.

Xiong R, Gao JL, Yin T. G3BP1 activates the TGF-β/Smad signaling pathway to promote gastric cancer. Onco Targets Ther. 2019;2(12):7149–56. https://doi.org/10.2147/OTT.S213728.CrossRef

37.

Soukupova J, Malfettone A, Hyroššová P, et al. Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism. Sci Rep. 2017;7(1):12486. https://doi.org/10.1038/s41598-017-12837-y.CrossRefPubMedPubMedCentral

38.

Hua W, Ten Dijke P, Kostidis S, et al. TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cell Mol Life Sci. 2020;77(11):2103–23. https://doi.org/10.1007/s00018-019-03398-6.CrossRefPubMed

39.

Qi Y, Xu R. Roles of PLODs in collagen synthesis and cancer progression. Front Cell Dev Biol. 2018;28(6):66. https://doi.org/10.3389/fcell.2018.00066.CrossRef

40.

Yamada Y, Kato M, Arai T, et al. Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target. Mol Oncol. 2019;13(9):1898–912. https://doi.org/10.1002/1878-0261.12532.CrossRefPubMedPubMedCentral

41.

Mello AA, Leal MF, Rey JA, et al. Deregulated expression of SRC, LYN and CKB kinases by DNA methylation and its potential role in gastric cancer invasiveness and metastasis. PLoS ONE. 2015;10(10):e0140492. https://doi.org/10.1371/journal.pone.0140492.CrossRefPubMedPubMedCentral

42.

Wang Z, Han G, Liu Q, et al. Silencing of PYGB suppresses growth and promotes the apoptosis of prostate cancer cells via the NF-κB/Nrf2 signaling pathway. Mol Med Rep. 2018;18(4):3800–8. https://doi.org/10.3892/mmr.2018.9388.CrossRefPubMedPubMedCentral

43.

Xiao L, Wang W, Huangfu Q, et al. PYGB facilitates cell proliferation and invasion in non-small cell lung cancer through activating Wnt/β-catenin signaling. Biochem Cell Biol. 2020. https://doi.org/10.1139/bcb-2019-0445.CrossRefPubMed

44.

Murata T, Shimizu K, Watanabe Y, et al. Expression and role of phosphodiesterase 5 in human malignant melanoma cell line. Anticancer Res. 2010;30(2):355–8.PubMed

45.

Sponziello M, Verrienti A, Rosignolo F, et al. PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. Endocrine. 2015;50(2):434–41. https://doi.org/10.1007/s12020-015-0586-x.CrossRefPubMed

46.

Tinsley HN, Gary BD, Keeton AB, et al. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila). 2011;4(8):1275–84. https://doi.org/10.1158/1940-6207.CAPR-11-0095.CrossRefPubMedPubMedCentral

Title: Identification of metabolism-associated genes and construction of a prognostic signature in bladder cancer
Authors: Chengquan Shen
Jing Liu
Liping Wang
Zhijuan Liang
Haitao Niu
Yonghua Wang
Publication date: 01-12-2020
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-020-01627-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism

MAFG-AS1 aggravates the progression of pancreatic cancer by sponging miR-3196 to boost NFIX

LncRNA KCNQ1OT1 promotes cell proliferation, migration and invasion via regulating miR-129-5p/JAG1 axis in non-small cell lung cancer

Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies

Arginine deprivation: a potential therapeutic for cancer cell metastasis? A review

CREB1-induced miR-1204 promoted malignant phenotype of glioblastoma through targeting NR3C2

Keynote webinar | Spotlight on antibody–drug conjugates in cancer